On March 19, 2026, the FDA approved Wegovy HD -- a higher-dose semaglutide injection (7.2 mg) that produces more weight loss than any previous Wegovy formulation. Novo Nordisk expects it to hit pharmacies in April 2026. (See our semaglutide guide.)
It's the latest move in a fast-changing GLP-1 market, coming after the Wegovy pill approval in December 2025 and the ongoing FDA crackdown on compounded GLP-1s.
What Is Wegovy HD?
Wegovy HD is a once-weekly semaglutide injection at 7.2 mg -- triple the current standard dose of 2.4 mg. Same active ingredient as Ozempic and regular Wegovy, just concentrated higher.
The FDA gave it a Commissioner's National Priority Voucher, which fast-tracked the review to just 54 days. That's a clear signal that regulators see the obesity treatment gap as urgent.
STEP UP Trial Results
The approval rests on the STEP UP trial -- a 72-week study of 1,407 adults with obesity (BMI 30+) who didn't have diabetes: (See our BMI calculator.)
- 21% average body weight loss on Wegovy HD, compared to 18% on the standard 2.4 mg dose and 2% on placebo
- 31% of patients lost 25% or more of their body weight -- vs. 15% on standard dose and 0% on placebo
- 91% hit at least 5% weight loss
In patients with type 2 diabetes (the STEP UP T2D trial), the 7.2 mg dose produced 14.1% mean weight loss and dropped A1C by 1.7-2.0%.
These are the best results for any semaglutide injection so far, though they still trail next-generation drugs like retatrutide (29% in trials).
Who Is Eligible?
Wegovy HD isn't something you start on. You have to:
- Be an adult with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition
- Already be tolerating the 2.4 mg Wegovy dose for at least 4 weeks
- Have a clinical reason for needing more weight loss than the 2.4 mg delivered
So this is a step-up for patients who've plateaued on the standard dose -- not a starting point. If you're new to GLP-1 treatment, our step-by-step prescription guide is the place to begin.
Side Effects
The side effect profile is in line with other GLP-1 medications, with a couple of things worth noting:
- Nausea, vomiting, and constipation -- the standard GI side effects, though most patients handle the step-up okay since they've already adjusted to 2.4 mg
- Altered skin sensation (dysesthesia) -- showed up in 22% of HD patients versus 6% on the 2.4 mg dose. This is a new finding and the FDA is watching it closely.
- Hair loss -- higher rates than the standard dose. See our guide on GLP-1 medications and hair loss.
- Just 3.3% of patients dropped out due to GI side effects
When and Where Will It Be Available?
Novo Nordisk says Wegovy HD launches in April 2026 through:
- 70,000+ US pharmacies including CVS and Costco
- Select telehealth providers
- NovoCare Pharmacy
- GoodRx and other savings platforms
Final pricing isn't out yet, but expect it to land in a similar range to current Wegovy. Manufacturer savings programs and insurance coverage should apply. If you're on Medicare, check our Medicare GLP-1 coverage update. (See our GLP-1 insurance coverage guide.) (See our GLP-1 pricing guide.) (See our savings calculator.)
The Bigger Picture: 2026 Is Reshaping GLP-1 Treatment
Wegovy HD enters a field that's getting crowded fast:
- Wegovy pill (25 mg oral semaglutide) -- already available, with 400,000 Americans on it just 10 weeks after launch
- Orforglipron (Eli Lilly) -- an oral GLP-1 with no dietary restrictions, expected to get FDA approval within weeks
- Retatrutide (Eli Lilly) -- a triple-hormone drug showing 29% weight loss in Phase 3 trials
- Medicare access growing -- a $50/month GLP-1 demonstration program launches in July 2026
For patients, all of this means more choices, stronger results, and prices trending down. The FDA's drug safety and availability portal tracks all new approvals and safety updates. For clinics, keeping up with new formulations isn't optional anymore. (See our Medicare GLP-1 coverage.)
What Should You Do?
If you're on Wegovy 2.4 mg and haven't hit your weight loss goal:
- Ask your provider whether stepping up to 7.2 mg makes sense for your situation
- Don't switch on your own -- the dose increase needs to be monitored
- Confirm insurance coverage for the new dose before making the switch
- Know about the new side effects -- especially the skin sensation changes that are more common at this dose
If you're not on a GLP-1 yet but thinking about it, Wegovy HD doesn't change your first step: find a qualified provider who can figure out whether GLP-1 treatment is right for you.
Find a Weight Loss Clinic That Offers Wegovy
Search our directory to find clinics prescribing Wegovy near you. With 2,800+ clinics across every US state, you can filter by medication, telehealth availability, and location. Browse clinics in Los Angeles, New York, Houston, and Miami.